Brain structure and neurocognitive development in sickle cell disease; a longitudinal cohort study (BRICK study)

Brain structure and neurocognitive development in sickle cell disease; a longitudinal cohort study (BRICK study) - BRICK

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51702

Enrollment

114

Registered

2021-12-22

Start date

2022-05-27

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sickle Cell Disease

Interventions

nvt

Eligibility

Age

2 Years to 64 Years

Inclusion criteria

Inclusion criteria: • Patients with sickle cell disease of all genotypes;

Exclusion criteria

Exclusion criteria: • Parents/ guardians (in case of minors) or patients themselves (>16 years) unable to make an informed decision on participating in this study. • An abnormal brain MRI prior to initiation of the study due to non-SCD related causes. • Contraindications for brain MRI per protocol

Design outcomes

Primary

Measure	Time frame
• Total white matter volume increase in children and adolescents with SCD	—

Secondary

Measure	Time frame
• Neurocognitive functioning (intelligence, specific neurocognitive functions, network organization) • Incidence of stroke • Other forms complications due to SCD • Amount of hospital admissions, day care admissions (adult care only), crises at home, contact moments with the sickle cell center, ER visits • Biomarkers for anemia, hemolysis, inflammation and endothelial activation. • Behavioral functioning	—

Measure

Time frame

• Neurocognitive functioning (intelligence, specific neurocognitive functions, network organization) • Incidence of stroke • Other forms complications due to SCD • Amount of hospital admissions, day care admissions (adult care only), crises at home, contact moments with the sickle cell center, ER visits • Biomarkers for anemia, hemolysis, inflammation and endothelial activation. • Behavioral functioning

—

Countries

Netherlands

Contacts

Public ContactMH Cnossen

Erasmus MC, Universitair Medisch Centrum Rotterdam

m.cnossen@erasmusmc.nl010-7036691

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)